

UC Davis

UC Davis Previously Published Works

Title

Noninvasive vs invasive respiratory support for patients with acute hypoxemic respiratory failure

Permalink

<https://escholarship.org/uc/item/84h7t087>

Journal

PLOS ONE, 19(9)

ISSN

1932-6203

Authors

Mosier, Jarrod M
Subbian, Vignesh
Pungitore, Sarah
[et al.](#)

Publication Date

2024

DOI

10.1371/journal.pone.0307849

Peer reviewed

RESEARCH ARTICLE

Noninvasive vs invasive respiratory support for patients with acute hypoxemic respiratory failure

Jarrold M. Mosier^{1,2*}, Vignesh Subbian^{3,4,5}, Sarah Pungitore⁶, Devashri Prabhudesai^{5,7}, Patrick Essay³, Edward J. Bedrick^{5,7}, Jacqueline C. Stocking⁸, Julia M. Fisher^{4,5,7}

1 Department of Emergency Medicine, The University of Arizona College of Medicine, Tucson, Arizona, United States of America, **2** Division of Pulmonary, Allergy, Critical Care, and Sleep, Department of Medicine, The University of Arizona College of Medicine, Tucson, Arizona, United States of America, **3** Department of Systems and Industrial Engineering, College of Engineering, The University of Arizona, Tucson, Arizona, United States of America, **4** Department of Biomedical Engineering, College of Engineering, The University of Arizona, Tucson, Arizona, United States of America, **5** BIO5 Institute, The University of Arizona, Tucson, Arizona, United States of America, **6** Program in Applied Mathematics, The University of Arizona, Tucson, Arizona, United States of America, **7** Statistics Consulting Laboratory, The University of Arizona, Tucson, Arizona, United States of America, **8** Pulmonary, Critical Care, and Sleep, Department of Medicine, UC Davis, Sacramento, California, United States of America

* jmosier@aemrc.arizona.edu



OPEN ACCESS

Citation: Mosier JM, Subbian V, Pungitore S, Prabhudesai D, Essay P, Bedrick EJ, et al. (2024) Noninvasive vs invasive respiratory support for patients with acute hypoxemic respiratory failure. PLoS ONE 19(9): e0307849. <https://doi.org/10.1371/journal.pone.0307849>

Editor: Stefan Grosek, University Medical Centre Ljubljana (UMCL) / Faculty of Medicine, University Ljubljana (FM,UL), SLOVENIA

Received: February 16, 2024

Accepted: July 12, 2024

Published: September 6, 2024

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: <https://doi.org/10.1371/journal.pone.0307849>

Copyright: © 2024 Mosier et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data cannot be shared publicly per University of Arizona Health Sciences Research Administration and Banner

Abstract

Background

Noninvasive respiratory support modalities are common alternatives to mechanical ventilation in acute hypoxemic respiratory failure. However, studies historically compare noninvasive respiratory support to conventional oxygen rather than mechanical ventilation. In this study, we compared outcomes in patients with acute hypoxemic respiratory failure treated initially with noninvasive respiratory support to patients treated initially with invasive mechanical ventilation.

Methods

This is a retrospective observational cohort study between January 1, 2018 and December 31, 2019 at a large healthcare network in the United States. We used a validated phenotyping algorithm to classify adult patients (≥ 18 years) with eligible International Classification of Diseases codes into two cohorts: those treated initially with noninvasive respiratory support or those treated invasive mechanical ventilation only. The primary outcome was time-to-in-hospital death analyzed using an inverse probability of treatment weighted Cox model adjusted for potential confounders. Secondary outcomes included time-to-hospital discharge alive. A secondary analysis was conducted to examine potential differences between noninvasive positive pressure ventilation and nasal high flow.

Results

During the study period, 3177 patients met inclusion criteria (40% invasive mechanical ventilation, 60% noninvasive respiratory support). Initial noninvasive respiratory support was

Health Research Administration restrictions because of the data contain potentially identifying or sensitive patient information, and are owned by the Banner Health clinical data warehouse. Data are available for researchers who meet the criteria for access to confidential data and with institutional review board approval and a negotiated data use agreement with the University of Arizona. Please direct data use agreement requests to the University of Arizona Health Sciences Research Administration at UAHSContracts@email.arizona.edu.

Funding: This work was supported by: E.20124, J. M.M., Emergency Medicine Foundation, Fisher & Paykel Healthcare Directed Grant. Authors supported: Mosier, Subbian, Fisher. <https://www.emfoundation.org/grantee/past-grantees/Grantees-2020-2021> 1838745, V.S., National Science Foundation. Authors supported: Subbian. https://www.nsf.gov/awardsearch/showAward?AWD_ID=1838745 5T32HL007955, P.E., National Heart, Lung, and Blood Institute, Authors supported: Essay. <https://reporter.nih.gov/project-details/8680297> UL1 TR001860, J.C.S., National Center for Advancing Translational Sciences. Authors supported: Stocking. <https://reporter.nih.gov/search/pzhJ4ZAoSUelr6CoWSajpg/projects/K01HL168222>, J.C.S., National Heart, Lung, And Blood Institute. Authors supported: Stocking. <https://reporter.nih.gov/search/z70wGdlT2ESfrAcjDewhGA/project-details/10643357> The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.

Competing interests: Dr. Mosier's competing interest statement has been amended to the following: JMM has received meeting travel support from Fisher & Paykel Healthcare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

not associated with a decreased hazard of in-hospital death (HR: 0.65, 95% CI: 0.35–1.2), but was associated with an increased hazard of discharge alive (HR: 2.26, 95% CI: 1.92–2.67). In-hospital death varied between the nasal high flow (HR 3.27, 95% CI: 1.43–7.45) and noninvasive positive pressure ventilation (HR 0.52, 95% CI 0.25–1.07), but both were associated with increased likelihood of discharge alive (nasal high flow HR 2.12, 95 CI: 1.25–3.57; noninvasive positive pressure ventilation HR 2.29, 95% CI: 1.92–2.74).

Conclusions

These data show that noninvasive respiratory support is not associated with reduced hazards of in-hospital death but is associated with hospital discharge alive.

Introduction

Noninvasive respiratory support strategies utilize an external interface (e.g., facemask, helmet, nasal cannula) to deliver either pressure-based support in the form of continuous or bilevel positive airway pressures; or flow-based support in the form of nasal high flow. Noninvasive modalities, particularly pressure-based support, are recommended for acute exacerbations of chronic obstructive pulmonary disease or acute cardiogenic pulmonary edema [1]. Noninvasive respiratory support modalities are also increasingly used for patients with acute *de novo* hypoxemic respiratory failure, despite unclear data on which strategies are superior and safer, or the impact on outcomes [2–5].

Overall, noninvasive strategies likely reduce the need for intubation and consequently lower mortality compared to standard oxygen [2, 6–8]. However, intubation after failed noninvasive respiratory support is associated with prolonged intensive care unit (ICU) stays and excess mortality [9–16]. The main theory is that nonintubated patients with acute hypoxemic respiratory failure may produce injurious transpulmonary pressures that are inhomogeneously amplified [17] and accelerate lung injury (i.e., patient self-inflicted lung injury). Noninvasive modalities are typically compared to conventional oxygen with the primary outcome of intubation, either alone or in combination with mortality. The benefits of noninvasive respiratory support (improved respiratory mechanics, reduced work of breathing, and improved gas exchange), however, render noninvasive strategies a more appropriate comparison to mechanical ventilation. Data comparing noninvasive respiratory support to invasive mechanical ventilation after conventional oxygen, however, are lacking. The goal of this study was to explore that comparison by investigating the outcomes in patients with acute hypoxemic respiratory failure treated with initial noninvasive respiratory support compared to invasive mechanical ventilation.

Methods

Study design, setting, and participants

This retrospective cohort study used de-identified structured clinical data from the Banner Health Network clinical data warehouse. Banner Health spans 26 hospitals across six states in the western United States and uses the Cerner Millennium (Oracle Health, formerly Cerner Corporation, North Kansas City, MO, USA) electronic health record system. Data for all adult patients (≥ 18 years) admitted to the hospital between January 1, 2018 and December 31, 2019 were extracted on September 16, 2020. Patients were included if they had an admission

diagnosis consistent with the pertinent *International Classification of Diseases* (version 10) sub-codes for acute hypoxemic respiratory failure (J.96): J96.00, J96.01, J96.02, J96.20, J96.21, J96.22, J96.90, J96.91, and J96.92. Patients were excluded if they had a first treatment location other than emergency department, intensive care unit, stepdown unit, or medical/surgical unit. This work adheres to the STROBE reporting guidelines, guidelines from journal editors [18], and was approved by the University of Arizona (#1907780973) and Banner Health Institutional Review Boards (#483-20-0018).

Cohort assignment

We used a validated phenotyping algorithm to classify eligible cases by the sequence of respiratory support [19–21] into two cohorts: those treated initially with noninvasive respiratory support and those treated initially with invasive mechanical ventilation. All patients in both cohorts were included in the analysis, as there is variation in the determination of failure and physiologic thresholds that prompt intubation [22]. Patients on conventional oxygen only were excluded. Secondary analyses were conducted separating noninvasive respiratory support into noninvasive positive pressure ventilation (either continuous or bilevel positive airway pressure) and nasal high flow. Noninvasive positive pressure ventilation, in any form, in the Banner Health System is provided using a noninvasive ventilator, and nasal high flow is delivered by either the Vapotherm (Vapotherm, Exeter, New Hampshire) system or the OptiFlow (Fisher & Paykel, Auckland, New Zealand) with or without the AirVo™ 2 system.

A subset of patients received noninvasive positive pressure ventilation, nasal high flow, and invasive mechanical ventilation. These patients were manually assigned to the appropriate cohort based on treatment start times and included for analyses comparing noninvasive support to mechanical ventilation but were excluded from analyses separating noninvasive support into noninvasive positive pressure ventilation and nasal high flow.

We estimated the propensity for invasive mechanical ventilation or noninvasive respiratory support (noninvasive positive pressure ventilation or nasal high flow separately in secondary analyses) by using generalized boosted models and used inverse probability of treatment weighting in the models to account for non-random treatment assignment [23], mirroring our previous comparisons in patients with COVID-19 associated respiratory failure [20]. The variables for propensity score estimation included age, body mass index, sex, ethnicity (non-Hispanic, Hispanic), race (white, other), respiratory rate and SpO₂/FiO₂ ratio immediately prior to first treatment, comorbidities (diabetes, chronic kidney disease, heart failure, hypertension, chronic obstructive pulmonary disease, neoplasm/immunosuppression, chronic liver disease, obesity), diagnoses of influenza or sepsis, vasopressor infusion before first treatment, first treatment location (emergency department, intensive care unit, stepdown, medical/surgical unit), hospital, time period of hospital admission (time period 1 [January 1—June 30, 2018], time period 2 [July 1—December 31, 2018], time period 3 [January 1—June 30, 2019], and time period 4 [July 1—December 31, 2019]), and hours from hospital admission to first treatment, transformed via the Box-Cox method with negatives [24]. Hospitals with <30 observations were grouped together for ease of modeling and to preserve de-identification. These variables were additionally included in later modeling to further improve balance between treatment groups.

Outcomes and data analysis

The primary outcome was time-to-in-hospital death, defined as time from initiation of respiratory support to death with hospital discharge considered a competing event. It was modeled using a cause-specific Cox model with the first treatment (noninvasive respiratory support

versus invasive mechanical ventilation) as the key predictor. A secondary outcome of time-to-hospital discharge alive was also evaluated using the same method. Each outcome was also evaluated with secondary analyses separating noninvasive respiratory support into noninvasive positive pressure ventilation and nasal high flow and a sensitivity analysis that removed patients with evidence of all three treatments. We assessed the proportional hazard assumption in the Cox models by including an interaction of time with first treatment and reported the model with the interaction if it was statistically significant at $\alpha = 0.05$. Then, due to limitations of hazard ratios in the presence of competing events, we estimated cumulative incidence curves associated with each treatment using the Cox model estimates [25]. We explored cumulative incidence curves associated with the comorbidities of heart failure and chronic obstructive pulmonary disease and diagnoses of influenza or sepsis both individually and in combination. We set the remaining covariate values to their sample median (continuous covariates) or most frequent value (categorical covariates) [26, 27]. The unweighted outcomes of mortality, intubation rate, days to intubation, and duration of mechanical ventilation were assessed using Fisher's Exact and Kruskal-Wallis rank sum tests where appropriate. We also conducted a subgroup analysis on the primary outcome after excluding patients with a comorbidity of chronic obstructive pulmonary disease or a body mass index >35 . Finally, E values for the hazard ratios and hazard ratio confidence limits closest to one are shown in order to estimate how much residual confounding would need to be present to have the true hazard ratio (or limit) be one; the higher the E value, the larger the residual confounding would need to be [28].

Electronic health record data requires accounting for varying levels of missingness among variables [29–31]. Missing data were handled by using multiple imputation by chained equations [32, 33]. For each analysis, we created 50 imputed data sets using all variables in the propensity score, the Nelson-Aalen estimate of the cumulative hazard rate function of available time-to-event data, the time-to-event, and event (i.e., in-hospital death, hospital discharge alive). Body mass index, SpO₂/FiO₂, and respiratory rate were imputed via predictive mean matching. Sex, ethnicity, race, and comorbidities were imputed with logistic regression. All variables used for propensity score estimation and the outcome variables were used to model any variables with missing data with the exception that raw time-to-event was not used to predict other variables in the multiple imputation by chained equations algorithm. Instead, temporal information was used for predicting missing values via the Nelson-Aalen estimate. We estimated propensity scores for each imputed data set separately. For the Cox models, the propensity scores from a specific imputed data set were used for inverse probability of treatment weighting for that data set [32, 33], and results were combined using Rubin's Rules. All data preprocessing and statistical analyses were done using R version 4.1.0 [34] with the following packages: *twang* [35], *survival* [36, 37], *survminer* [38], *mice* [32], *xtable* [39], and *tidyverse* [40]. Further detailed descriptions of data preprocessing can be found in our previous work [20].

Results

There were 3177 patients who met the inclusion criteria. Of these, 1266 (40%) were intubated initially while 1911 (60%) were initially treated with noninvasive respiratory support, Fig 1 and Table 1. There are important differences between cohorts. Patients intubated initially were more commonly male (55% vs. 49%) and disproportionately at large hospitals (57% vs. 44%). They were also of higher acuity based on median APACHE score (68 vs. 49), although only patients admitted to an ICU were given an APACHE score in the electronic health record. Those intubated initially were less likely to have comorbid heart failure (36% vs. 47%) or




Fig 1. STROBE diagram of included subjects. There were 89,002 total visits during the study period. Of those, most (85,825) failed to meet exclusion criteria. *The subjects that were excluded because they were not classified by the algorithm but had an eligible diagnostic code on admission likely represent those only requiring conventional oxygen. Repeat admissions and interhospital transfers were excluded due to confounding with the outcome.

<https://doi.org/10.1371/journal.pone.0307849.g001>

chronic obstructive pulmonary disease (68% vs. 85%), more likely to be septic (36% vs. 19%), and had more severe hypoxemia based on $\text{SpO}_2/\text{FiO}_2$ on treatment assignment (medians 130 vs. 261, difference of means 90.52, 95% CI: 84.04–97.01) despite clinically similar worst $\text{PaO}_2/\text{FiO}_2$ in the first 24 hours (medians 124 vs. 142, difference of means 4.59, 95% CI: -4.39–13.58). Of the 1850 (97%) patients where the sequence of noninvasive respiratory support could be reliably classified, most patients (96%) were treated with noninvasive positive pressure ventilation (S1 Table: Demographics). All-cause in-hospital mortality was 13%, higher for patients intubated first than for those treated with noninvasive respiratory support first (18% vs 9%), S2 Table: Unmatched Outcomes. Mortality was significantly higher for noninvasive respiratory support patients who required intubation compared to those who did not (22% vs. 6%).

Hazard ratios are shown in Table 2. Initial noninvasive respiratory support was not associated with a decreased hazard of in-hospital death (HR: 0.65, 95% CI: 0.35–1.2); with no significant interaction of treatment and time and a reasonable protection from unmeasured confounders with an E-value of 2.04. Initial noninvasive respiratory support was, however, associated with an increased hazard of discharge alive (HR: 2.26, 95% CI: 1.92–2.67) that decreased over time (interaction between time and noninvasive respiratory support HR: 0.97, 95% CI: 0.95–0.98) and an even stronger E-value (2.90), Fig 2. The subgroup analysis excluding patients with comorbid chronic obstructive pulmonary disease or a body mass index >35 showed no statistically significant association between initial respiratory support modality and time to in-hospital death, but the hazard ratio increased for noninvasive respiratory support compared to mechanical ventilation (1.71, 95% CI: 0.85–3.45), with an E-value of 2.25. Sensitivity analyses excluding the patients without clear treatment sequence shows noninvasive

Table 1. Demographics.

Measure	Invasive Mechanical Ventilation	Noninvasive Respiratory Support	Total
N (%)	1266 (40%)	1911 (60%)	3177
Female Sex	574 (45%)	970 (51%)	1544 (49%)
Age, median (IQR)	61 (48–72)	68 (58–77)	66 (54–75)
BMI, median (IQR)	28 (23–35)	29 (23–37)	28 (23–36)
Ethnicity, n(%) ^a			
Not Hispanic or Latino	1031 (82%)	1645 (86%)	2676 (85%)
Hispanic or Latino	225 (18%)	261 (14%)	486 (15%)
Race, n (%) ^a			
White	1078 (82%)	1690 (89%)	2768 (88%)
Black or African American	76 (6%)	105 (6%)	181 (6%)
Asian/Native Hawaiian/Pacific Islander	16 (1%)	18 (1%)	34 (1%)
American Indian or Alaska Native	62 (5%)	39 (2%)	101 (3%)
Other	25 (2%)	53 (3%)	78 (2%)
Hospital Size, n(%)			
small	39 (4%)	158 (9%)	197 (7%)
medium	428 (39%)	815 (47%)	1243 (44%)
large	631 (57%)	779 (44%)	1410 (49%)
APACHE IVa median (IQR)	68 (50–87)	49 (38–63)	57 (43–76)
Vital Signs on Treatment Assignment median (IQR)			
Heart rate	93 (79–112)	88 (75–104)	90 (76–107)
Systolic blood pressure	120 (103–140)	132 (116–149)	127 (111–146)
Diastolic blood pressure	68 (57–82)	73 (64–83)	71 (61–83)
SpO ₂	98 (96–100)	96 (93–98)	97 (94–99)
FiO ₂ ^b	75 (50–100)	36 (30–50)	45 (33–80)
SpO ₂ :FiO ₂	130 (99–200)	261 (186–323)	200 (116–297)
Temperature (°C)	37 (36.6–37)	36.8 (36.5–37)	36.9 (36.5–37)
Respiratory Rate	19 (16–23)	20 (18–25)	20 (18–24)
Comorbidities n(%)			
Diabetes	468 (40%)	756 (40%)	1224 (40%)
Chronic Kidney Disease	261 (22%)	527 (28%)	788 (26%)
Heart Failure	418 (36%)	903 (47%)	1321 (43%)
Hypertension	839 (72%)	1427 (75%)	2266 (74%)
Chronic Liver Disease	242 (21%)	157 (8%)	399 (13%)
Neoplasm or Immunosuppression	175 (15%)	293 (15%)	468 (15%)
COPD	799 (68%)	1613 (85%)	2412 (78%)
Obesity	186 (16%)	350 (18%)	536 (17%)
Acute Influenza Diagnosis	2 (0%)	4 (0%)	6 (0%)
Acute sepsis diagnosis	419 (36%)	354 (19%)	773 (25%)
Labs on Admission median (IQR)			
PaO ₂ (mmHg) (Worst Value)	79 (65–107)	75 (63–102)	77 (63–104)
PaO ₂ :FiO ₂ (Worst Value)	124 (79–220)	142 (84–218)	133 (81–218)
White Blood Cell Count (K/uL)	8 (2.45–14)	7.7 (2–13)	7.9 (2–13.5)
Lactate (mmol/L)	1.9 (1.2–3.7)	1.5 (1–2.3)	1.7 (1.1–2.8)
pH	7.31 (7.19–7.39)	7.33 (7.26–7.41)	7.33 (7.24–7.4)
PaCO ₂ (mmHg)	46 (38–64)	53 (40–70)	50 (38–68)
HCO ₃ (mmol/L)	24 (20–28)	27 (23–32)	26 (22–30)
BNP (pg/mL)	1490 (359–5781)	1316 (327–5381)	1369 (334–5476)

(Continued)

Table 1. (Continued)

Measure	Invasive Mechanical Ventilation	Noninvasive Respiratory Support	Total
Creatinine (mg/dL)	1.0 (0.76–1.58)	0.95 (0.73–1.36)	0.97 (0.74–1.43)
Time from hospital admission to treatment (h)	0.6 (0–7)	27 (0–89)	6 (0–61)
Treatment Assignment Location n (%) ^a			
Emergency Department	666 (53%)	523 (27%)	1189 (37%)
ICU	505 (40%)	644 (34%)	1149 (36%)
Non-ICU ward	16 (1%)	272 (14%)	288 (9%)
Stepdown	79 (6%)	472 (25%)	551 (17%)

^a Data are presented as percent of available.

^b FiO₂ determined by documented FiO₂, if documented, or by $FiO_2 = 100(0.21 + \text{oxygen flow [L/min}^{-1}] \times 0.03$ if a flow rate was documented.

<https://doi.org/10.1371/journal.pone.0307849.t001>

respiratory support was associated with a reduced hazard of in-hospital death (HR: 0.53, 95% CI: 0.28–0.99, E-value 2.49) and an increased hazard of hospital discharge alive (HR: 2.34, 95% CI: 1.97–2.77, E-value 2.98) that again decreased over time (interaction between time and non-invasive respiratory support HR: 0.97, 95% CI: 0.95–0.98). Representative cumulative incidence curves show a consistent trend of slightly reduced probability of in-hospital death and increased probability of discharge alive for noninvasive respiratory support across a range of comorbidities (chronic obstructive pulmonary disease, congestive heart failure) and diagnoses (influenza, sepsis), except for the subgroup analysis S1–S5 Figs. The cumulative incidence

Table 2. Cox model results.

Outcome	First Treatment	Hazard Ratio	95% CI	P-Value	E-Value	CL E-Value	
Time to In-Hospital Death	Primary analysis	NIRS	0.65	0.35–1.2	0.167	2.04	1.00
	Sensitivity analysis	NIRS	0.53	0.28, 0.99	0.047	2.49	1.08
	Subgroup analysis*	NIRS	1.71	0.85, 3.45	0.136	2.25	1.00
	Secondary analysis	NHF	3.27	1.43, 7.45	0.005	3.91	1.89
		NIPPV	0.52	0.25, 1.07	0.076	2.53	1.00
Time to Hospital Discharge Alive	Primary analysis	NIRS	2.26	1.92, 2.67	<0.001	2.90	2.51
		Time x NIRS	0.97	0.95, 0.98	<0.001	1.18	1.13
	Sensitivity analysis	NIRS	2.34	1.97, 2.77	<0.001	2.98	2.57
		Time x NIRS	0.97	0.95, 0.98	<0.001	1.18	1.14
	Secondary analysis	NHF	2.12	1.25, 3.57	0.005	2.74	1.62
		NIPPV	2.29	1.92, 2.74	<0.001	2.94	2.51
		Time x NHF	0.99	0.93, 1.05	0.795	1.08	1.00
		Time x NIPPV	0.96	0.95, 0.98	<0.001	1.19	1.14

NIRS = Noninvasive respiratory support

NHF = nasal high flow

NIPPV = noninvasive positive pressure ventilation

* excluding patients with comorbid chronic obstructive pulmonary disease or a body mass index >35. Note that for this analysis, we had to remove influenza from the propensity score calculation and regroup some hospitals due to the reduced sample size.

Additional predictors include age, BMI, gender, ethnicity, white race, respiratory rate (breaths/min), the ratio of SPO₂ to FIO₂, diabetes, CKD, hypertension, heart failure, COPD, neoplasm or immunosuppression, chronic liver disease, obesity, influenza, sepsis, vasopressors before treatment, transformed first treatment start (in days after hospital admission), first treatment location type (levels ED, ICU, Stepdown, or Med/Surg), hospital (with a grouped level for hospitals with very few patients in the data set), and time period.

<https://doi.org/10.1371/journal.pone.0307849.t002>




Fig 2. Top: Model-estimated cumulative incidence curves for noninvasive respiratory support (NIRS) vs invasive mechanical ventilation (IMV) showing the probabilities for hospital discharge alive (left) and in-hospital death (right). Bottom: Estimated time-varying hospital discharge alive hazard ratios for NIRS versus IMV with pointwise 95% confidence intervals. The following values were used for covariates: male, not Hispanic or Latino, white, one of the large hospitals (hospital A), hospital admission to the emergency department between January 1, 2018 and June 30, 2018, no vasopressor infusion before treatment, no diabetes, no chronic kidney disease, no heart failure, yes hypertension, no chronic obstructive pulmonary disease, no neoplasm/immunosuppression, no chronic liver disease, no obesity, no influenza, yes sepsis, and continuous covariates set at their median values (age = 66 years, $SpO_2/FiO_2 = 200$, respiratory rate = 20 breaths/min, BMI = 28.44, transformed hours from hospital admission to first treatment = 1.77). Each imputed data set generates a pair of curves (one for IMV, one for NIRS).

<https://doi.org/10.1371/journal.pone.0307849.g002>

curves in the subgroup analysis suggest an increased probability of in-hospital death with non-invasive respiratory support.

The probability of discharge alive is greater for NIRS than for IMV, and the probability of in-hospital death is lower. The hazard ratio of discharge alive for NIRS vs. IMV starts out statistically significantly positive shortly before 20 days after treatment initiation and eventually switches direction around 40 days.

In the secondary analyses separating noninvasive respiratory support modalities, the hazard for in-hospital death ranged from increased with nasal high flow (HR 3.27, 95% CI: 1.43–7.45, E-value 3.91) to non-significantly decreased with noninvasive positive pressure ventilation (HR 0.52, 95% CI 0.25–1.07, E-value 2.53), neither with an interaction with time, Fig 3. Both modalities were associated with increased hazard of discharge alive (nasal high flow HR 2.12, 95% CI: 1.25–3.57, E-value 2.74; noninvasive positive pressure ventilation HR 2.29, 95% CI: 1.92–2.74, E-value 2.94), both with strong E-values, but only noninvasive positive pressure ventilation showed an interaction with time (interaction between time and nasal high flow HR 0.99, 95% CI: 0.93–1.05; interaction between time and noninvasive positive pressure




Fig 3. Top: Model-estimated cumulative incidence curves for noninvasive positive pressure ventilation (NIPPV), nasal high flow (NHF), and invasive mechanical ventilation (IMV) showing the probabilities for hospital discharge alive (left) and in-hospital death (right). Bottom: Estimated time-varying hospital discharge alive hazard ratios for NHF versus IMV (left) and NIPPV versus IMV (right) with pointwise 95% confidence intervals.

<https://doi.org/10.1371/journal.pone.0307849.g003>

ventilation HR 0.96, 95% CI: 0.95–0.98). Representative cumulative incidence curves are shown in [S6](#) and [S7](#) Figs.

The following values were used for covariates: male, not Hispanic or Latino, white, one of the large hospitals (hospital A), hospital admission to the emergency department between January 1, 2018 and June 30, 2018, no vasopressor infusion before treatment, no diabetes, no chronic kidney disease, no heart failure, yes hypertension, no chronic obstructive pulmonary disease, no neoplasm/immunosuppression, no chronic liver disease, no obesity, no influenza, yes sepsis, and continuous covariates set at their median values (age = 66 years, SpO₂/FiO₂ = 200, respiratory rate = 20 breaths/min, BMI = 28.44, transformed hours from hospital admission to first treatment = 1.70). Each imputed data set generates a triple of curves (one for IMV, NHF, and NIPPV).

Patients initially treated with either non-invasive modality had a higher probability of hospital discharge alive until roughly 15 days after treatment initiation. After that, the probability of discharge alive remained higher for NIPPV compared to IMV but reversed direction for NHF and IMV. Nasal high flow had a slightly higher probability of in-hospital death than IMV, and NIPPV had a slightly lower probability of in-hospital death than IMV. The hospital discharge alive hazard ratio of NHF to IMV was positive but decreasing until around day 15, at which point there was no further clear difference between those two treatments. The same pattern held for the hospital discharge alive hazard ratio of NIPPV to IMV except that it eventually reversed direction, resulting in the hazard of hospital discharge alive being greater for IMV than NIPPV starting at roughly 35 days after treatment initiation.

Discussion

Noninvasive respiratory support strategies are increasingly used as alternative initial strategies to early intubation and mechanical ventilation for patients with acute hypoxemic respiratory failure. Thus, the goal of this study was to compare the outcomes between those two approaches. Our results show that initial noninvasive respiratory support modalities in patients with acute hypoxemic respiratory failure were most likely not associated with a reduced hazard of in-hospital death (no association in the primary analyses, weakly significant association in the sensitivity analysis), yet were associated with an increased probability of hospital discharge alive when compared to initial invasive mechanical ventilation. The existing literature comparing noninvasive strategies to conventional oxygen suggests that noninvasive respiratory support is probably associated with reduced mortality, reduced intubation, and shorter hospital stays, but to varying degrees among the different noninvasive modalities [2, 4, 5, 41, 42]. Our results expand upon this knowledge by comparing outcomes between noninvasive strategies and invasive mechanical ventilation in non-COVID-19 acute hypoxemic respiratory failure. Despite patients who were intubated first generally being more severely ill and more likely to be septic, there was no increase in hazard of our primary outcome (in-hospital death). However, noninvasive respiratory support was associated with an increased likelihood of hospital discharge alive, which waned over time for nasal high flow. Further study may show that failure of a noninvasive respiratory support modality may be associated with increased mortality beyond the progression of disease, thus having an outsized influence on the overall association with mortality [43]. This hypothesis is supported by the observed 3.5-fold increase in unweighted mortality for patients that failed a noninvasive strategy compared to those that did not, and is also suggested by the results of our subgroup analysis.

These data suggest that noninvasive respiratory support modalities can be effective alternatives to mechanical ventilation for the initial treatment of some patients with acute hypoxemic respiratory failure. Successful noninvasive support increases the likelihood of earlier hospital

discharge, but an unsuccessful trial may carry outsized consequences for mortality. These results add to findings from the Lung Safe study, that showed noninvasive positive pressure ventilation was used in 15% of patients with acute respiratory distress syndrome, but both failure and mortality increased as the severity of disease worsened [15]. While spontaneous breathing can have some advantages in acute hypoxemic respiratory failure patients, patient self-inflicted lung injury is the likely reason for worse outcomes in patients that fail a noninvasive strategy [44, 45]. Taking these data and existing literature together, balancing the double-edged sword with noninvasive respiratory support involves early application of noninvasive respiratory support with close monitoring of the patient's work of breathing and avoiding delayed intubation in patients where noninvasive modalities fail to sufficiently reduce the work of breathing [46].

Our secondary analyses also suggested differences between noninvasive positive pressure ventilation and nasal high flow. There are four possible explanations for these findings. The first is that noninvasive positive pressure may be the better noninvasive strategy. The second possibility is that the patients treated with nasal high flow may not have been similar to the patients treated with noninvasive positive pressure ventilation, and that our efforts to account for treatment confounding were not fully successful. Patients treated with nasal high flow in our dataset had a higher median APACHE score on admission (56 vs. 48, difference of means 11.77, 95% CI: 6.36, 17.18) a lower median SpO₂/FiO₂ on treatment assignment (136 vs 274, difference of means -105, 95% CI: -126 - -85) and lower median worst PaO₂/FiO₂ (76 vs 150, difference of means -76, 95% CI: -106 - -45), more commonly had neoplasm or immunosuppression (26% vs 15%) and were more commonly septic (34% vs 17%). The third possibility is that patients may not have been treated similarly. Patients initiated on noninvasive positive pressure in a non-intensive care unit were more commonly transferred to the intensive care unit by 12 hours than patients started on nasal high flow (32% vs 12%). Lastly, there may have been imbalanced, imprecise, or incorrect delivery of one modality compared to the other. The median flow rate for nasal high flow was 40lpm (95% CI: 35 - 50lpm). While gas exchange can improve at lower flow rates, higher flow rates are required for the work of breathing benefits related to changes in resting lung volume and strain [47]. Monitoring likely differed between intensive care (e.g., work of breathing changes, signs of fatigue) and non-intensive care units (e.g., oxygen saturation). Additionally, managing failure could have differed as failing nasal high flow could have resulted in more crossover to noninvasive positive pressure ventilation than intubation compared to failing noninvasive positive pressure ventilation.

There are important limitations to our results. Our data were limited to pre-COVID-19 data. As such, the use of noninvasive respiratory support modalities has likely evolved as is evident by the relatively low number of patients treated with nasal high flow across the entire health network. Second, we used admission diagnostic codes to select patients treated at the time for acute hypoxemic respiratory failure without the selection bias of using discharge diagnostic codes. These results are contingent upon accurate coding of admission diagnoses and important patient groups may have been excluded. Since these data are non-randomized observational data, non-protocolized clinical care may have contributed unmeasured confounding differences in the selection for and management of each modality. We attempted to control for confounding by inverse probability for treatment assignment weighting and further adjusting for potential confounders in the Cox models. Furthermore, our E-values are relatively strong, so any unmeasured confounding would have needed to have a substantial effect to alter the results. Another limitation is that results are based on the first assigned therapy, and symptom onset time is not available in our dataset. Thus, crossover (and imbalanced crossover), and symptom duration could confound the findings. Lastly, goals of care and end-of-life issues are not readily extractable from structured electronic health record data. There is

an important difference between a patient who is a do-not-intubate on admission treated with rescue noninvasive respiratory support and a similar patient who worsened during noninvasive respiratory support and chose to become a do-not-intubate. However, both patients would have been included in our dataset and could contribute some confounding in the results.

Despite these limitations, our results provide an overview of outcomes between respiratory support modalities that were pragmatically applied across a large healthcare network. These results highlight important knowledge gaps needing further study, including: 1. the risks of failing noninvasive respiratory support, mechanisms of those risks, thresholds of, monitoring for, and management of failure, 2. reproducible phenotypes likely to do well or not do well with noninvasive respiratory support modality, 3. optimal noninvasive support modality by phenotype, 4. optimal noninvasive respiratory support delivery by modality and, 5. optimal hospital location and minimal monitoring capabilities for patients with acute hypoxemic respiratory failure requiring noninvasive respiratory support.

Our data across a large and diverse healthcare network show that initial treatment with noninvasive respiratory support is not associated with a reduced hazard of in-hospital death compared to invasive mechanical ventilation for patients admitted with acute hypoxemic respiratory failure. However, noninvasive respiratory support is associated with a higher likelihood of earlier hospital discharge. Lastly, our data suggest potential differences between noninvasive respiratory support modalities that require further exploration.

Supporting information

S1 Table. Demographics of patients without clear sequence of support.

(DOCX)

S2 Table. Unmatched outcomes.

(DOCX)

S1 Fig. Representative in-hospital death-model cumulative incidence curves.

(DOCX)

S2 Fig. Representative in-hospital death-model cumulative incidence curves excluding patients without clear sequence of noninvasive respiratory support.

(DOCX)

S3 Fig. Representative in-hospital death-model cumulative incidence curves of a subgroup excluding patients with a comorbidity of COPD or body mass index >35.

(DOCX)

S4 Fig. Representative hospital discharge alive model-estimated cumulative incidence curves.

(DOCX)

S5 Fig. Representative hospital discharge alive model-estimated cumulative incidence curves excluding patients without clear sequence representative hospital discharge alive model-estimated cumulative incidence curves excluding patients without clear sequence of noninvasive respiratory support.

(DOCX)

S6 Fig. Representative in-hospital death model-estimated cumulative incidence curves excluding patients without clear sequence of noninvasive respiratory support.

(DOCX)

S7 Fig. Representative hospital discharge alive model-estimated cumulative incidence curves excluding patients without clear sequence of noninvasive respiratory support.
(DOCX)

Acknowledgments

The authors would like to thank Don Saner and Mario Arteaga from the Banner Health Network Clinical Data Warehouse for their support during this project.

Author Contributions

Conceptualization: Jarrod M. Mosier, Vignesh Subbian, Patrick Essay, Edward J. Bedrick, Jacqueline C. Stocking, Julia M. Fisher.

Data curation: Jarrod M. Mosier, Vignesh Subbian, Sarah Pungitore, Devashri Prabhudesai, Patrick Essay, Julia M. Fisher.

Formal analysis: Jarrod M. Mosier, Vignesh Subbian, Sarah Pungitore, Devashri Prabhudesai, Patrick Essay, Edward J. Bedrick, Jacqueline C. Stocking, Julia M. Fisher.

Funding acquisition: Jarrod M. Mosier, Vignesh Subbian, Patrick Essay, Julia M. Fisher.

Investigation: Jarrod M. Mosier, Vignesh Subbian, Sarah Pungitore, Patrick Essay, Julia M. Fisher.

Methodology: Jarrod M. Mosier, Vignesh Subbian, Patrick Essay, Edward J. Bedrick, Julia M. Fisher.

Project administration: Jarrod M. Mosier.

Resources: Vignesh Subbian.

Supervision: Jarrod M. Mosier, Vignesh Subbian, Edward J. Bedrick, Julia M. Fisher.

Validation: Julia M. Fisher.

Visualization: Jarrod M. Mosier, Devashri Prabhudesai, Edward J. Bedrick, Jacqueline C. Stocking, Julia M. Fisher.

Writing – original draft: Jarrod M. Mosier, Julia M. Fisher.

Writing – review & editing: Jarrod M. Mosier, Vignesh Subbian, Sarah Pungitore, Devashri Prabhudesai, Patrick Essay, Edward J. Bedrick, Jacqueline C. Stocking, Julia M. Fisher.

References

1. Rochweg B, Brochard L, Elliott MW, Hess D, Hill NS, Nava S, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. *The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology*. 2017; 50(2). <https://doi.org/10.1183/13993003.02426-2016> PMID: 28860265
2. Ferreyro BL, Angriman F, Munshi L, Del Sorbo L, Ferguson ND, Rochweg B, et al. Association of Non-invasive Oxygenation Strategies With All-Cause Mortality in Adults With Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-analysis. *JAMA: the journal of the American Medical Association*. 2020; 324(1):57–67. <https://doi.org/10.1001/jama.2020.9524> PMID: 32496521
3. Rochweg B, Einav S, Chaudhuri D, Mancebo J, Mauri T, Helviz Y, et al. The role for high flow nasal cannula as a respiratory support strategy in adults: a clinical practice guideline. *Intensive Care Med*. 2020; 46(12):2226–37. <https://doi.org/10.1007/s00134-020-06312-y> PMID: 33201321
4. Pitre T, Zeraatkar D, Kachkovski GV, Leung G, Shligold E, Dowhanik S, et al. Noninvasive Oxygenation Strategies in Adult Patients With Acute Hypoxemic Respiratory Failure: A Systematic Review and Network Meta-Analysis. *Chest*. 2023. <https://doi.org/10.1016/j.chest.2023.04.022> PMID: 37085046

5. Chaudhuri D, Trivedi V, Lewis K, Rochweg B. High-Flow Nasal Cannula Compared With Noninvasive Positive Pressure Ventilation in Acute Hypoxic Respiratory Failure: A Systematic Review and Meta-Analysis. *Crit Care Explor.* 2023; 5(4):e0892. <https://doi.org/10.1097/CCE.0000000000000892> PMID: 37007904
6. Ni YN, Luo J, Yu H, Liu D, Ni Z, Cheng J, et al. Can High-flow Nasal Cannula Reduce the Rate of Endotracheal Intubation in Adult Patients With Acute Respiratory Failure Compared With Conventional Oxygen Therapy and Noninvasive Positive Pressure Ventilation?: A Systematic Review and Meta-analysis. *Chest.* 2017; 151(4):764–75.
7. Shen Y, Zhang W. High-flow nasal cannula versus noninvasive positive pressure ventilation in acute respiratory failure: interaction between PaO₂/FiO₂ and tidal volume. *Crit Care.* 2017; 21(1):285. <https://doi.org/10.1186/s13054-017-1861-4> PMID: 29166943
8. Zhao H, Wang H, Sun F, Lyu S, An Y. High-flow nasal cannula oxygen therapy is superior to conventional oxygen therapy but not to noninvasive mechanical ventilation on intubation rate: a systematic review and meta-analysis. *Crit Care.* 2017; 21(1):184. <https://doi.org/10.1186/s13054-017-1760-8> PMID: 28701227
9. Antonelli M, Conti G, Moro ML, Esquinas A, Gonzalez-Diaz G, Confalonieri M, et al. Predictors of failure of noninvasive positive pressure ventilation in patients with acute hypoxemic respiratory failure: a multi-center study. *Intensive Care Med.* 2001; 27(11):1718–28. <https://doi.org/10.1007/s00134-001-1114-4> PMID: 11810114
10. Carrillo A, Gonzalez-Diaz G, Ferrer M, Martinez-Quintana ME, Lopez-Martinez A, Llamas N, et al. Non-invasive ventilation in community-acquired pneumonia and severe acute respiratory failure. *Intensive Care Med.* 2012; 38(3):458–66. <https://doi.org/10.1007/s00134-012-2475-6> PMID: 22318634
11. Demoule A, Girou E, Richard JC, Taille S, Brochard L. Benefits and risks of success or failure of noninvasive ventilation. *Intensive Care Med.* 2006; 32(11):1756–65. <https://doi.org/10.1007/s00134-006-0324-1> PMID: 17019559
12. Chandra D, Stamm JA, Taylor B, Ramos RM, Satterwhite L, Krishnan JA, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998–2008. *American Journal of Respiratory and Critical Care Medicine.* 2012; 185(2):152–9. <https://doi.org/10.1164/rccm.201106-1094OC> PMID: 22016446
13. Walkey AJ, Wiener RS. Use of noninvasive ventilation in patients with acute respiratory failure, 2000–2009: a population-based study. *Annals of the American Thoracic Society.* 2013; 10(1):10–7. <https://doi.org/10.1513/AnnalsATS.201206-034OC> PMID: 23509327
14. Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. *JAMA: the journal of the American Medical Association.* 2016; 315(8):788–800. <https://doi.org/10.1001/jama.2016.0291> PMID: 26903337
15. Bellani G, Laffey JG, Pham T, Madotto F, Fan E, Brochard L, et al. Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome. Insights from the LUNG SAFE Study. *Am J Respir Crit Care Med.* 2017; 195(1):67–77. <https://doi.org/10.1164/rccm.201606-1306OC> PMID: 27753501
16. Thille AW, Contou D, Fragnoli C, Cordoba-Izquierdo A, Boissier F, Brun-Buisson C. Non-invasive ventilation for acute hypoxemic respiratory failure: intubation rate and risk factors. *Crit Care.* 2013; 17(6):R269. <https://doi.org/10.1186/cc13103> PMID: 24215648
17. Brochard L, Slutsky A, Pesenti A. Mechanical Ventilation to Minimize Progression of Lung Injury in Acute Respiratory Failure. *Am J Respir Crit Care Med.* 2017; 195(4):438–42. <https://doi.org/10.1164/rccm.201605-1081CP> PMID: 27626833
18. Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. *Annals of the American Thoracic Society.* 2019; 16(1):22–8. <https://doi.org/10.1513/AnnalsATS.201808-564PS> PMID: 30230362
19. Essay P, Mosier J, Subbian V. Rule-Based Cohort Definitions for Acute Respiratory Failure: Electronic Phenotyping Algorithm. *JMIR Med Inform.* 2020; 8(4):e18402. <https://doi.org/10.2196/18402> PMID: 32293579
20. Fisher J, Subbian V, Essay P, Pungitore S, Bedrick E, Mosier J. Acute Respiratory Failure from Early Pandemic COVID-19: Noninvasive Respiratory Support vs Mechanical Ventilation. *CHEST Critical Care.* 2023. <https://doi.org/10.1016/j.chstcc.2023.100030> PMID: 38645483
21. Essay P, Fisher JM, Mosier JM, Subbian V. Validation of an Electronic Phenotyping Algorithm for Patients With Acute Respiratory Failure. *Crit Care Explor.* 2022; 4(3):e0645. <https://doi.org/10.1097/CCE.0000000000000645> PMID: 35261979

22. Yarnell CJ, Johnson A, Dam T, Jonkman A, Liu K, Wunsch H, et al. Do Thresholds for Invasive Ventilation in Hypoxemic Respiratory Failure Exist? A Cohort Study. *Am J Respir Crit Care Med*. 2023; 207(3):271–82. <https://doi.org/10.1164/rccm.202206-1092OC> PMID: 36150166
23. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. *Statistics in medicine*. 2013; 32(19):3388–414. <https://doi.org/10.1002/sim.5753> PMID: 23508673
24. Hawkins D, Weisberg S. Combining the Box-Cox Power and Generalized Log Transformations to Accommodate Nonpositive Responses in Linear and Mixed-Effects Linear Models. *South African Statist J*. 2017; 5:317–28.
25. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. *Statistics in medicine*. 2007; 26(11):2389–430. <https://doi.org/10.1002/sim.2712> PMID: 17031868
26. Bhattacharjee S, Patanwala AE, Lo-Ciganic WH, Malone DC, Lee JK, Knapp SM, et al. Alzheimer's disease medication and risk of all-cause mortality and all-cause hospitalization: A retrospective cohort study. *Alzheimers Dement (N Y)*. 2019; 5:294–302. <https://doi.org/10.1016/j.trci.2019.05.005> PMID: 31338414
27. Eekhout I, van de Wiel MA, Heymans MW. Methods for significance testing of categorical covariates in logistic regression models after multiple imputation: power and applicability analysis. *BMC Med Res Methodol*. 2017; 17(1):129. <https://doi.org/10.1186/s12874-017-0404-7> PMID: 28830466
28. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*. 2017; 167(4):268–74. <https://doi.org/10.7326/M16-2607> PMID: 28693043
29. Haneuse S, Daniels M. A General Framework for Considering Selection Bias in EHR-Based Studies: What Data Are Observed and Why? *EGEMS (Wash DC)*. 2016; 4(1):1203. <https://doi.org/10.13063/2327-9214.1203> PMID: 27668265
30. Botsis T, Hartvigsen G, Chen F, Weng C. Secondary Use of EHR: Data Quality Issues and Informatics Opportunities. *Summit Transl Bioinform*. 2010; 2010:1–5. PMID: 21347133
31. van der Lei J. Use and abuse of computer-stored medical records. *Methods Inf Med*. 1991; 30(2):79–80. PMID: 1857252
32. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. *Journal of Statistical Software*. 2011; 45(3):1–67.
33. White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. *Statistics in medicine*. 2011; 30(4):377–99. <https://doi.org/10.1002/sim.4067> PMID: 21225900
34. Team RC. R: A language and environment for statistical computing.: R Foundation for Statistical Computing. Vienna, Austria; 2020.
35. Cefalu M, Ridgeway G, McCaffrey D, A. M. twang: Toolkit for Weighting and Analysis of Nonequivalent Groups. R Package version 2.5 2021. <https://CRAN.R-project.org/package=twang>.
36. T T. A Package for Survival Analysis in R. R package version 3.1–12. 2020.
37. Therneau T, Grambsch P. Modeling Survival Data: Extending the Cox Model. 1 ed. New York: Springer; 2000. 350 p.
38. Kassambara A, Kosinski M, Biecek P. survminer: Drawing Survival Curves using 'ggplot2.' R package version 0.4.9 2021. <https://CRAN.R-project.org/package=survminer>.
39. Dahl DB, Scott D, Roosen C, Magnusson A, Swinton J. xtable: Export Tables to LaTeX or HTML. R package version 1.8–4. 2019.
40. Wickham H, Averick M, Bryan J, Chang W, al. e. Welcome to the tidyverse. *Journal of Open Source Software*. 2019; 4(43):1686.
41. Rochweg B, Granton D, Wang DX, Helviz Y, Einav S, Frat JP, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: a systematic review and meta-analysis. *Intensive Care Med*. 2019; 45(5):563–72. <https://doi.org/10.1007/s00134-019-05590-5> PMID: 30888444
42. Ni YN, Luo J, Yu H, Liu D, Liang BM, Yao R, et al. Can high-flow nasal cannula reduce the rate of reintubation in adult patients after extubation? A meta-analysis. *BMC pulmonary medicine*. 2017; 17(1):142. <https://doi.org/10.1186/s12890-017-0491-6> PMID: 29149868
43. Essay P, Mosier JM, Nayebi A, Fisher JM, Subbian V. Predicting Failure of Noninvasive Respiratory Support Using Deep Recurrent Learning. *Respiratory care*. 2022. <https://doi.org/10.4187/respcare.10382> PMID: 36543341
44. Grieco DL, Menga LS, Raggi V, Bongiovanni F, Anzellotti GM, Tanzarella ES, et al. Physiological Comparison of High-Flow Nasal Cannula and Helmet Noninvasive Ventilation in Acute Hypoxemic Respiratory Failure. *Am J Respir Crit Care Med*. 2020; 201(3):303–12. <https://doi.org/10.1164/rccm.201904-0841OC> PMID: 31687831

45. Tonelli R, Fantini R, Tabbi L, Castaniere I, Pisani L, Pellegrino MR, et al. Early Inspiratory Effort Assessment by Esophageal Manometry Predicts Noninvasive Ventilation Outcome in De Novo Respiratory Failure. A Pilot Study. *Am J Respir Crit Care Med*. 2020; 202(4):558–67. <https://doi.org/10.1164/rccm.201912-2512OC> PMID: 32325004
46. Mosier JM, Tidswell M, Wang HE. Noninvasive respiratory support in the emergency department: Controversies and state-of-the-art recommendations. *J Am Coll Emerg Physicians Open*. 2024; 5(2): e13118. <https://doi.org/10.1002/emp2.13118> PMID: 38464331
47. Vieira F, Bezerra FS, Coudroy R, Schreiber A, Telias I, Dubo S, et al. High Flow Nasal Cannula compared to Continuous Positive Airway Pressure: a bench and physiological study. *Journal of applied physiology*. 2022. <https://doi.org/10.1152/jappphysiol.00416.2021> PMID: 35511720